Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,024 across all filing types
Latest filing 2017-08-25 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-08-25 English
FORM 4
Director's Dealing
2017-08-25 English
FORM S-3/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-3/A Registration Statement Amendment No. 3 filed with the SEC by BioCardia, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for public offering, with a shelf registration allowing sales up to $50 million. The document includes details about the types of securities to be offered, the registration fee, and legal disclaimers. It is not a financial report, earnings release, or management discussion, but rather a capital raising and securities offering filing. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities.
2017-08-25 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel to the SEC regarding an Amendment No. 2 to a Registration Statement on Form S-3 filed by BioCardia, Inc. It references updates to the Registration Statement, including incorporation of the company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2017. The letter also mentions filing an updated consent from the independent registered public accounting firm. The document is a correspondence related to regulatory filings and amendments to registration statements, not the actual financial report or registration statement itself. It is short (3070 characters) and serves as a communication or response to the SEC rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2017-08-25 English
FORM 10-Q
Interim / Quarterly Report Q2 2017
2017-08-14 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel responding to comments from the SEC staff regarding amendments to a Registration Statement on Form S-3 and an Amendment No. 1 to Form 10-K for the fiscal year ended December 31, 2016. The letter discusses specific details about beneficial ownership and exhibits related to the 10-K amendment. The document is a correspondence addressing SEC comments rather than the actual 10-K report itself. It is relatively short (4864 characters) and serves as a regulatory response rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related submission and not the full Annual Report (10-K) or an Audit Report (AR).
2017-08-08 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.